A Randomized Phase II Study of Reolysin For Patients Receiving Standard Weekly Paclitaxel Therapy as Therapy For Advanced/Metastatic Breast Cancer

Trial Profile

A Randomized Phase II Study of Reolysin For Patients Receiving Standard Weekly Paclitaxel Therapy as Therapy For Advanced/Metastatic Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Pelareorep (Primary) ; Paclitaxel
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Aug 2017 According to an Oncolytics Biotech media release, the US FDA has granted Fast Track designation for REOLYSIN (pelareorep) for the treatment of metastatic breast cancer (mBC). The designation is based on the data from this trial.
    • 27 Apr 2017 According to an Oncolytics Biotech media release, results from this trial will be discussed in 2017 Annual Meeting of Shareholders.
    • 12 Apr 2017 According to an Oncolytics Biotech media release, the company intends to present data from this study to regulators as part of an End-of-Phase 2 Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top